Edoxaban is an oral
direct factor Xa inhibitor for prophylaxis and treatment of thromboembolic disorders. The effects on common coagulation assays are clinically valuable information and in certain clinical situations a quick assessment of the
anticoagulant is wanted. Our aim was to investigate the effect of
edoxaban on routine coagulation methods and evaluate anti-Xa assays, commonly used for other
direct factor Xa inhibitors, for estimation of the
drug concentration.
Edoxaban was spiked to plasma samples from healthy subjects in the concentration range 0-742 µg/L and analyzed using different
reagents for activated partial thromboplastin time (APTT) and prothrombin time (PT). Assays for
antithrombin,
activated protein C resistance,
lupus anticoagulant (LA) and chromogenic anti-Xa assays were also included.
Edoxaban displayed similar effects in vitro to other oral direct Xa inhibitors. The concentration needed to double the coagulation time varied between assays and
reagents; 539-758 µg/L for the APTT and between 329 and 2505 µg/L for the PT.
Edoxaban gave false high
antithrombin activities in assays based on Xa-inhibition. Two integrated assays for LA, both based on activation with dilute
Russell's viper venom, displayed different results. Chromogenic anti-Xa assays displayed linear dose-response curves with
edoxaban up to approximately 500 µg/L. In conclusion, therapeutic concentrations of
edoxaban variably affect different coagulation assays, and even different
reagents within an assay group. In comparison with other oral Xa-inhibitors, the in vitro effects of
edoxaban were more similar to
rivaroxaban than
apixaban. For measurement of
edoxaban concentration in plasma, it is possible to use the chromogenic anti-Xa assays.